Dr. Reddy's Laboratories Ltd. and Bristol Myers Squibb’s Celgene have reached a settlement agreement in patent-litigation proceedings stemming from the Indian firm’s development of a generic version of the originator’s Pomalyst (pomalidomide) capsules.
Dr Reddy’s And BMS Shake Hands On Pomalyst Settlement
Final Judgment Says Reddy’s Does Not Infringe Key Drug Substance Patent
Bristol Myers Squibb does not “expect generic entry in the US market prior to the first quarter of 2026” for its Pomalyst treatment for relapsed and refractory multiple myeloma, after reaching a settlement agreement with ANDA sponsor Dr Reddy’s Laboratories.
More from Deals
• By
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
• By
Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.
• By
Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
More from Business
• By
Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.
• By
Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.